NCT05041309
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Enrolling by invitation
Phase 2
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: 
Additional Notes: Patients must have completed Kite-sponsored parent study (NCT03139370)
Exclusions: 
https://ClinicalTrials.gov/show/NCT05041309